GoAI
Get started
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc.

ARTV

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$10.93

−$0.21 · -1.89%

Aug 21, 4:00 PM ET

ARTV company overview

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

23

Expensive

Momentum

64

Gaining

Sentiment

61

Bullish

Risk resilience

29

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $10.93

52-week range

Current $10.93

Open
$11.33
Previous close
$11.14
Volume
199.42K
Market cap
534.37M USD
50-day average
$10.1152
+8.06% above average
200-day average
$7.0117
+55.88% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.3×
P/B (TTM)
1.24×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.03×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2791%-7972%-18734%-29496%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Operating margin, FY2021: -2660.94%Operating margin, FY2022: -1213.32%Operating margin, FY2023: -91.58%Operating margin, FY2024: -26805.58%Net margin, FY2021: -3587.66%Net margin, FY2022: -1184.10%Net margin, FY2023: -82.69%Net margin, FY2024: -23303.98%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Operating margin FY2021 -2660.94%. Operating margin FY2022 -1213.32%. Operating margin FY2023 -91.58%. Operating margin FY2024 -26805.58%. Net margin FY2021 -3587.66%. Net margin FY2022 -1184.10%. Net margin FY2023 -82.69%. Net margin FY2024 -23303.98%.

Income trends

Revenue

251K USD-99.25%

Operating income

−90.61M USD-34.67%

Net income

−83.87M USD-43.38%
Income trends across reported periods45.9M USD−3.74M USD−53.38M USD−103.02M USDRevenue, FY2021: 2M USDRevenue, FY2022: 4.93M USDRevenue, FY2023: 33.49M USDRevenue, FY2024: 251K USDOperating income, FY2021: −53.27M USDOperating income, FY2022: −59.83M USDOperating income, FY2023: −30.67M USDOperating income, FY2024: −67.28M USDOperating income, FY2025: −90.61M USDNet income, FY2021: −71.83M USDNet income, FY2022: −58.39M USDNet income, FY2023: −27.7M USDNet income, FY2024: −58.49M USDNet income, FY2025: −83.87M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2M USD. Revenue FY2022 4.93M USD. Revenue FY2023 33.49M USD. Revenue FY2024 251K USD. Operating income FY2021 −53.27M USD. Operating income FY2022 −59.83M USD. Operating income FY2023 −30.67M USD. Operating income FY2024 −67.28M USD. Operating income FY2025 −90.61M USD. Net income FY2021 −71.83M USD. Net income FY2022 −58.39M USD. Net income FY2023 −27.7M USD. Net income FY2024 −58.49M USD. Net income FY2025 −83.87M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—251K USD33.49M USD4.93M USD2M USD
Cost of goods sold2.6M USD————
Gross profit−2.6M USD251K USD33.49M USD4.93M USD2M USD
Research and development69.54M USD50.33M USD50.25M USD43.98M USD42.41M USD
Selling, general, and administrative20.27M USD17.21M USD13.91M USD20.78M USD12.86M USD
Operating expenses88.01M USD67.53M USD64.16M USD64.76M USD55.27M USD
Interest income5.96M USD5.35M USD2.54M USD1.29M USD—
Depreciation and amortization2.6M USD2.43M USD2.27M USD1.16M USD248K USD
Operating income−90.61M USD−67.28M USD−30.67M USD−59.83M USD−53.27M USD
Net income−83.87M USD−58.49M USD−27.7M USD−58.39M USD−71.83M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-3.43
FY2025
Latest fiscal-year revenue
0 USD
FY2025 · -100.00% year over year
Next fiscal-year EPS consensus
-2.59
FY2026 · 5 analysts
Next fiscal-year revenue consensus
1.68M USD
FY2028 · 5 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.79-2.39-4-5.6FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend227.97M145.07M62.17M-20.72MFY21FY22FY23FY24FY25FY28FY29FY30

ARTV news

defenseworld.net

Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies…

Read source
globenewswire.com

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient…

Read source
globenewswire.com

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with…

Read source
zacks.com

Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?

Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.

Read source
globenewswire.com

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with…

Read source
globenewswire.com

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis Late-breaking…

Read source

ARTV peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ARTV

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.07M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.72M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
1.54M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
1.11M
Weight
1.30%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.8186-0.20%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
400.06K
Weight
0.00%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
305.53K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
263.3K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
178.15K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research ARTV

research.disclaimer